Indivior PLC (INDVL.XC)
- Previous Close
870.50 - Open
862.75 - Bid 855.00 x --
- Ask 857.50 x --
- Day's Range
854.00 - 878.00 - 52 Week Range
554.50 - 1,458.50 - Volume
59,026 - Avg. Volume
106,046 - Market Cap (intraday)
1.071B - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-0.04 - Earnings Date Jul 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 16, 2016
- 1y Target Est
--
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
www.indivior.com1,030
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: INDVL.XC
View MorePerformance Overview: INDVL.XC
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INDVL.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INDVL.XC
View MoreValuation Measures
Market Cap
1.09B
Enterprise Value
1.09B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.29
Price/Book (mrq)
--
Enterprise Value/Revenue
1.23
Enterprise Value/EBITDA
19.78
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.30%
Return on Assets (ttm)
12.60%
Return on Equity (ttm)
--
Revenue (ttm)
1.17B
Net Income Avi to Common (ttm)
-62M
Diluted EPS (ttm)
-0.04
Balance Sheet and Cash Flow
Total Cash (mrq)
373M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
264.88M